| Moderate risk | High risk | Very high risk | p |
---|---|---|---|---|
HbA1c ≤ 7.0% (%) | 57.4 | 58.0 | 51.6 |  < 0.0001 |
HbA1c > 8.0% (%) | 22.3 | 16.1 | 18.4 |  < 0.0001 |
Blood pressure ≥ 140/90 mmHg (%) | 0.0 | 31.0 | 50.8 |  < 0.0001 |
LDL Cholesterol < 100 mg/dl (%) | 49.8 | 54.7 | 65.6 |  < 0.0001 |
LDL Cholesterol ≥ 130 mg/dl (%) | 0.0 | 9.1 | 13.1 |  < 0.0001 |
Subjects with HbA1c ≤ 7.0%, with C-LDL < 100 mg/dl and with BP < 140/90 mmHg (%) | 31.0 | 24.3 | 18.6 |  < 0.0001 |
BMI ≥ 30 kg/m2(%) | 0.0 | 14.7 | 46.6 |  < 0.0001 |
Subjects not treated with insulin despite HbA1c ≥ 9.0% (%)a | 39.2 | 38.4 | 25.5 |  < 0.0001 |
Subjects with HbA1c ≥ 9.0% despite insulin therapy (%)b | 31.6 | 18.2 | 15.7 |  < 0.0001 |
Subjects not treated with anti-hypertensive despite BP ≥ 140/90 mmHg (%)c | n.a | 48.2 | 22.5 |  < 0.0001 |
Subjects with BP ≥ 140/90 mmHg despite anti-hypertensive therapy (%)d | n.a | 46.8 | 48.8 |  < 0.0001 |
Subjects not treated with lipid-lowering drugs despite C-LDL ≥ 130 mg/dl (%)e | n.a | 60.1 | 45.5 |  < 0.0001 |
Subjects with C-LDL ≥ 130 mg/dl despite lipid-lowering therapy (%)f | n.a | 16.9 | 9.7 |  < 0.0001 |
Subjects with a previous CV event (heart attack and/or stroke) treated with antiplatelet therapy (%) | n.a | n.a | 76.1 | - |
Mean Q Score | 32.2 ± 6.8 | 30.1 ± 7.6 | 28.2 ± 8.3 |  < 0.0001 |
Subjects with Q Score < 15 (%) | 0.0 | 1.6 | 4.1 |  < 0.0001 |
Subjects with Q Score > 25 (%) | 74.0 | 66.1 | 59.4 |  < 0.0001 |